| Title |
Challenging the effectiveness of green tea in primary and tertiary cancer prevention
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, June 2012
|
| DOI | 10.1007/s00432-012-1250-y |
| Pubmed ID | |
| Authors |
Hirota Fujiki, Kazue Imai, Kei Nakachi, Masahito Shimizu, Hisataka Moriwaki, Masami Suganuma |
| Abstract |
Drinking green tea daily is part of Japanese culture, and various studies have revealed that green tea is a cancer preventive. We here review our progress in cancer prevention with green tea on 12 main topics, from basic to clinical level. TOPICS AND METHODS: Biochemical and biological studies of green tea catechins, a prospective cohort study, preclinical safety trials with tablets of green tea extract, double-blind randomized clinical phase II prevention trial for recurrence of colorectal adenomas, and synergistically enhanced inhibition by the combination of green tea catechins and anticancer drugs. All results were significant, including human studies with informed consent. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 11% |
| Japan | 1 | 11% |
| Canada | 1 | 11% |
| Unknown | 6 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Italy | 1 | 2% |
| Canada | 1 | 2% |
| Unknown | 60 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 21% |
| Researcher | 7 | 11% |
| Student > Master | 7 | 11% |
| Student > Ph. D. Student | 6 | 10% |
| Lecturer | 4 | 6% |
| Other | 11 | 17% |
| Unknown | 15 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 24% |
| Agricultural and Biological Sciences | 8 | 13% |
| Chemistry | 6 | 10% |
| Nursing and Health Professions | 5 | 8% |
| Computer Science | 2 | 3% |
| Other | 9 | 14% |
| Unknown | 18 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2020.
All research outputs
#1,306,443
of 23,864,690 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#33
of 2,658 outputs
Outputs of similar age
#7,511
of 167,885 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#2
of 22 outputs
Altmetric has tracked 23,864,690 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,658 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 167,885 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.